# Eli Lilly and Company

> Eli Lilly and Company is a 150-year-old Indianapolis pharmaceutical maker that discovers, develops, manufactures and sells medicines in roughly 90 countries. Once known for insulin and Prozac, it is now the engine behind the GLP-1 obesity-and-diabetes boom, with tirzepatide (Mounjaro and Zepbound) driving it past $65 billion in annual revenue and, for stretches of 2024-2026, the title of the world's most valuable healthcare company.

- **Founded:** 1876
- **Headquarters:** Indianapolis, Indiana, United States
- **Founders:** Eli Lilly (Founder (Colonel, pharmaceutical chemist))
- **Team size:** ~51,000 employees worldwide (about 25% in R&D)
- **Products:** Mounjaro (tirzepatide), Zepbound (tirzepatide), Trulicity (dulaglutide), Verzenio (abemaciclib), Kisunla (donanemab)
- **Notable:** Reached roughly a $1 trillion market capitalization, among the most valuable healthcare companies in the world., Tirzepatide (Mounjaro + Zepbound) generated about $36.5 billion in 2025, roughly 56% of total revenue., Among the first companies to mass-produce insulin (1923) and penicillin, and the first to make a human-health product via recombinant DNA (Humulin, 1982).

## Products & services

- **Mounjaro (tirzepatide)** — GIP/GLP-1 receptor agonist injection for type 2 diabetes; one of the fastest-growing drugs in pharmaceutical history.
- **Zepbound (tirzepatide)** — Same molecule as Mounjaro, approved for chronic weight management and obstructive sleep apnea in adults with obesity.
- **Trulicity (dulaglutide)** — Once-weekly GLP-1 injection for type 2 diabetes, a prior flagship diabetes product.
- **Verzenio (abemaciclib)** — CDK4/6 inhibitor for HR-positive, HER2-negative breast cancer.
- **Kisunla (donanemab)** — Amyloid-targeting antibody infusion for early symptomatic Alzheimer's disease.
- **Jardiance (empagliflozin)** — SGLT2 inhibitor for type 2 diabetes, heart failure and chronic kidney disease, co-developed with Boehringer Ingelheim.
- **Taltz (ixekizumab)** — IL-17A inhibitor for plaque psoriasis, psoriatic arthritis and related conditions.
- **Ebglyss (lebrikizumab)** — IL-13 inhibitor for moderate-to-severe atopic dermatitis.
- **Orforglipron (Foundayo)** — First approved oral small-molecule GLP-1 receptor agonist for obesity and weight management.
- **Humalog / Humulin (insulin)** — Insulin franchises; Humulin was the first human-health product made with recombinant DNA technology.

## Achievements

- Reached roughly a $1 trillion market capitalization, among the most valuable healthcare companies in the world.
- Tirzepatide (Mounjaro + Zepbound) generated about $36.5 billion in 2025, roughly 56% of total revenue.
- Among the first companies to mass-produce insulin (1923) and penicillin, and the first to make a human-health product via recombinant DNA (Humulin, 1982).
- Launched Kisunla (donanemab) for early Alzheimer's disease in 2024.
- Secured approval of orforglipron, the first oral small-molecule GLP-1 for obesity, in 2026.
- Marked 150 years of continuous operation headquartered in Indianapolis in May 2026.

## Latest updates

- **2026-08** — Q2 2026 earnings beat estimates; full-year 2026 revenue guidance raised to $85-$87 billion on surging Zepbound and Mounjaro demand.
- **2026-04** — Orforglipron (Foundayo), the first oral small-molecule GLP-1 for obesity, received U.S. approval; Q1 2026 Mounjaro revenue rose 125% to $8.7 billion.
- **2026-02** — Reported Q4 2025 results and issued 2026 guidance; full-year 2025 revenue reached $65.18 billion.
- **2026-05** — Company marked its 150th anniversary in Indianapolis, with CEO David Ricks reflecting on its history and pipeline.

## Links

- Website: https://lilly.com
- LinkedIn: http://www.linkedin.com/company/eli-lilly-and-company
- Twitter/X: https://twitter.com/LillyPad
- YouTube: https://www.youtube.com/user/EliLillyandCo
- Instagram: https://www.instagram.com/lillypad/
- Facebook: https://www.facebook.com/elilillyandco

---

Profile page: https://yespress.io/eli-lilly-and-company
Published by YesPress — https://yespress.io
Last updated: 2026-08-12